SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity. / Nielsen, Stine Sofie Frank; Vibholm, Line Khalidan; Johannsen, Ida Monrad et al.

I: EBioMedicine, Bind 68, 103410, 06.2021.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Nielsen SSF, Vibholm LK, Johannsen IM, Olesen R, Frattari G, Pahus MH et al. SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity. EBioMedicine. 2021 jun.;68:103410. doi: 10.1016/j.ebiom.2021.103410

Author

Bibtex

@article{c3f947ab2a8b4233bf4c902b6b2de478,
title = "SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity",
abstract = "Background: The SARS-CoV-2 pandemic currently prevails worldwide. To understand the immunological signature of SARS-CoV-2 infections and aid the search and evaluation of new treatment modalities and vaccines, comprehensive characterization of adaptive immune responses towards SARS-CoV-2 is needed.Methods: We included 203 recovered SARS-CoV-2 infected patients in Denmark between April 3rd and July 9th 2020, at least 14 days after COVID-19 symptom recovery. The participants had experienced a range of disease severities from asymptomatic to severe. We collected plasma, serum and PBMC's for analysis of SARS-CoV-2 specific antibody response by Meso Scale analysis including other coronavirus strains, ACE2 competition, IgA ELISA, pseudovirus neutralization capacity, and dextramer flow cytometry analysis of CD8+ T cells. The immunological outcomes were compared amongst severity groups within the cohort, and 10 pre-pandemic SARS-CoV-2 negative controls.Findings: We report broad serological profiles within the cohort, detecting antibody binding to other human coronaviruses. 202(>99%) participants had SARS-CoV-2 specific antibodies, with SARS-CoV-2 neutralization and spike-ACE2 receptor interaction blocking observed in 193(95%) individuals. A significant positive correlation (r=0.7804) between spike-ACE2 blocking antibody titers and neutralization potency was observed. Further, SARS-CoV-2 specific CD8+ T-cell responses were clear and quantifiable in 95 of 106(90%) HLA-A2+ individuals.Interpretation: The viral surface spike protein was identified as the dominant target for both neutralizing antibodies and CD8+ T-cell responses. Overall, the majority of patients had robust adaptive immune responses, regardless of their disease severity.Funding: This study was supported by the Danish Ministry for Research and Education (grant# 0238-00001B) and The Danish Innovation Fund (grant# 0208-00018B)",
keywords = "Adaptive, Antibody, Asymptomatic, CD8 T-cell, COVID-19, Corona, Immune response, SARS-CoV-2, Severe, Virus",
author = "Nielsen, {Stine Sofie Frank} and Vibholm, {Line Khalidan} and Johannsen, {Ida Monrad} and Rikke Olesen and Giacomo Frattari and Pahus, {Marie H{\o}st} and H{\o}jen, {Jesper Falkesgaard} and {Damsgaard Gunst}, Jesper and Christian Erikstrup and Andreas Holleufer and Rune Hartmann and {\O}stergaard, {Lars J{\o}rgen} and S{\o}gaard, {Ole Schmeltz} and Schleimann, {Mariane H{\o}gsbjerg} and Martin Tolstrup",
year = "2021",
month = jun,
doi = "10.1016/j.ebiom.2021.103410",
language = "English",
volume = "68",
journal = "EBioMedicine",
issn = "2352-3964",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity

AU - Nielsen, Stine Sofie Frank

AU - Vibholm, Line Khalidan

AU - Johannsen, Ida Monrad

AU - Olesen, Rikke

AU - Frattari, Giacomo

AU - Pahus, Marie Høst

AU - Højen, Jesper Falkesgaard

AU - Damsgaard Gunst, Jesper

AU - Erikstrup, Christian

AU - Holleufer, Andreas

AU - Hartmann, Rune

AU - Østergaard, Lars Jørgen

AU - Søgaard, Ole Schmeltz

AU - Schleimann, Mariane Høgsbjerg

AU - Tolstrup, Martin

PY - 2021/6

Y1 - 2021/6

N2 - Background: The SARS-CoV-2 pandemic currently prevails worldwide. To understand the immunological signature of SARS-CoV-2 infections and aid the search and evaluation of new treatment modalities and vaccines, comprehensive characterization of adaptive immune responses towards SARS-CoV-2 is needed.Methods: We included 203 recovered SARS-CoV-2 infected patients in Denmark between April 3rd and July 9th 2020, at least 14 days after COVID-19 symptom recovery. The participants had experienced a range of disease severities from asymptomatic to severe. We collected plasma, serum and PBMC's for analysis of SARS-CoV-2 specific antibody response by Meso Scale analysis including other coronavirus strains, ACE2 competition, IgA ELISA, pseudovirus neutralization capacity, and dextramer flow cytometry analysis of CD8+ T cells. The immunological outcomes were compared amongst severity groups within the cohort, and 10 pre-pandemic SARS-CoV-2 negative controls.Findings: We report broad serological profiles within the cohort, detecting antibody binding to other human coronaviruses. 202(>99%) participants had SARS-CoV-2 specific antibodies, with SARS-CoV-2 neutralization and spike-ACE2 receptor interaction blocking observed in 193(95%) individuals. A significant positive correlation (r=0.7804) between spike-ACE2 blocking antibody titers and neutralization potency was observed. Further, SARS-CoV-2 specific CD8+ T-cell responses were clear and quantifiable in 95 of 106(90%) HLA-A2+ individuals.Interpretation: The viral surface spike protein was identified as the dominant target for both neutralizing antibodies and CD8+ T-cell responses. Overall, the majority of patients had robust adaptive immune responses, regardless of their disease severity.Funding: This study was supported by the Danish Ministry for Research and Education (grant# 0238-00001B) and The Danish Innovation Fund (grant# 0208-00018B)

AB - Background: The SARS-CoV-2 pandemic currently prevails worldwide. To understand the immunological signature of SARS-CoV-2 infections and aid the search and evaluation of new treatment modalities and vaccines, comprehensive characterization of adaptive immune responses towards SARS-CoV-2 is needed.Methods: We included 203 recovered SARS-CoV-2 infected patients in Denmark between April 3rd and July 9th 2020, at least 14 days after COVID-19 symptom recovery. The participants had experienced a range of disease severities from asymptomatic to severe. We collected plasma, serum and PBMC's for analysis of SARS-CoV-2 specific antibody response by Meso Scale analysis including other coronavirus strains, ACE2 competition, IgA ELISA, pseudovirus neutralization capacity, and dextramer flow cytometry analysis of CD8+ T cells. The immunological outcomes were compared amongst severity groups within the cohort, and 10 pre-pandemic SARS-CoV-2 negative controls.Findings: We report broad serological profiles within the cohort, detecting antibody binding to other human coronaviruses. 202(>99%) participants had SARS-CoV-2 specific antibodies, with SARS-CoV-2 neutralization and spike-ACE2 receptor interaction blocking observed in 193(95%) individuals. A significant positive correlation (r=0.7804) between spike-ACE2 blocking antibody titers and neutralization potency was observed. Further, SARS-CoV-2 specific CD8+ T-cell responses were clear and quantifiable in 95 of 106(90%) HLA-A2+ individuals.Interpretation: The viral surface spike protein was identified as the dominant target for both neutralizing antibodies and CD8+ T-cell responses. Overall, the majority of patients had robust adaptive immune responses, regardless of their disease severity.Funding: This study was supported by the Danish Ministry for Research and Education (grant# 0238-00001B) and The Danish Innovation Fund (grant# 0208-00018B)

KW - Adaptive

KW - Antibody

KW - Asymptomatic

KW - CD8 T-cell

KW - COVID-19

KW - Corona

KW - Immune response

KW - SARS-CoV-2

KW - Severe

KW - Virus

U2 - 10.1016/j.ebiom.2021.103410

DO - 10.1016/j.ebiom.2021.103410

M3 - Journal article

C2 - 34098342

VL - 68

JO - EBioMedicine

JF - EBioMedicine

SN - 2352-3964

M1 - 103410

ER -